“Live Webinar on Scalable T-cell Expansion in Stirred-Tank Bioreactors” - Wednesday 24th October 2018

Emerging cell therapies, particularly T-cell-based treatments, indicate significant potential to treat a range of diseases in oncology and other areas of medicine. In order to scale-up these therapies for commercial product distribution one critical challenge in cell processing is a reliable process for culture expansion that can produce consistently high yields.

This webinar will be presented by Mr. Alex Klarer, Biomedical Engineer at Hitachi Chemical Advanced Therapeutic Solutions (previously PCT Cell Therapy) and will discuss the evaluation of the ambr 15 microbioreactor system as a small-scale model for a robust and potentially scalable solution for suspension cultures.

Mr Klarer will present proof-of-concept data for growing healthy donor-derived T-cells from three unique donors in a stirred-tank bioreactor.

During the webinar, Mr Klarer will present data on the following:

  • T-cell proliferation in stirred-tank bioreactors compared to a static culture
  • Key parameters of stirred-tank bioreactor cultures such as optimised bioreactor conditions

Join us for this live webinar on Wednesday 24th October:

8.00 am PDT (San Francisco)
11.00 am EDT (Boston)
4.00pm BST (London)
5.00pm CEST (Berlin)

Register now for the webinar

Register for this webinar and you will also receive an on-demand link which you can watch later or share with your colleagues.



About ambr® systems

ambr® systems are designed and manufactured by Sartorius Stedim Biotech (Royston, UK), a leading global provider of automated cell culture and fermentation systems for life science research, development and production

ambr systems are widely used for cell line development and process optimisation at pharmaceutical, biotechnology and academic laboratories. They are proven to provide a reliable model and consistent scalability to a range of upstream processes.


About Hitachi Chemical Advanced Therapeutics Solutions

Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS, formerly PCT Cell Therapy Services, LLC), is a wholly owned subsidiary of Hitachi Chemical Company, Ltd. (Hitachi Chemical) representing Hitachi Chemical’s Regenerative Medicine Business Sector in the United States. HCATS leverages nearly two decades of experience exclusively focused on the cell therapy industry. It provides contract development and manufacturing organization (CDMO) services at current Good Manufacturing Practices (cGMP) standards, including clinical manufacturing, commercial manufacturing, and manufacturing development.

Facilities to deliver these services under a global harmonized service platform have been established in Japan (Yokohama City, Kanagawa Prefecture), and in the United States (New Jersey and California), with an expansion to add commercial manufacturing capabilities and capacity underway in New Jersey.

For more information about these services, please visit